Project Grant R01AI148554
Award Date
3/17/21
Completion Date
7/12/21
Dollars Obligated
$1.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award of $585,145 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to develop novel regulatory CD8 T cell (CD8 Treg) immunotherapies to promote allograft tolerance in transplant recipients. The key objectives are to: 1) Identify HLA-E-binding superagonists that can selectively mobilize human CD8 Tregs to suppress alloreactive CD4 T cells, and 2)...
The University of Pittsburgh received a $679,937 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct research on mechanisms and therapeutic targeting of T cell regulation in heart allograft recipient monkeys. The 5-year project aims to investigate the impact of cytokine modulation and administration of novel, donor-specific chimeric antigen receptor regulatory T cells (CARTREG) on promoting long-term...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $500,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on modulating T cell activation to combat HIV persistence. The 5-year project, starting on September 1, 2024, aims to identify and perturb regulatory mechanisms governing antigen-refractory HIV-specific CD8+ T...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $195,819 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Duke University to conduct research on inducing xenotolerance, or immune tolerance to tissues from genetically modified pigs, as a potential solution to the shortage of organ donors for human transplantation. The specific aim is to determine the ability of cultured postnatal pig thymus slices to attract human immune cells and support their...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,529,805.00 to the University of Pittsburgh to conduct research on strategies to enhance regulatory myeloid cell function and improve renal transplant survival in non-human primates. The research aims to test three innovative approaches: 1) using an agonistic antibody against the LILRB3 receptor to extend...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $1,286,273 to The Trustees of Columbia University in the City of New York for preclinical studies on strategies to induce liver transplant tolerance. The key objectives are to: 1) Test the ability of BCL-2 inhibitors to promote durable chimerism and reduce induction regimen toxicity for simultaneous bone marrow and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to decipher the mechanisms leading to immune-related myocarditis, a fatal side effect of immune checkpoint inhibitor (ICI) cancer therapy. With $858,186 in total funding over a 5-year period from May 2025 to April 2030, the research team at The General Hospital Corporation (doing business as...
This $210,867 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a proof-of-concept study to develop a cell-based therapy for generating donor-specific immune tolerance in kidney transplant recipients. The key products/services to be delivered include: Engineering "push/pull" particle-loaded tolerogenic dendritic cells (PPP-TolDCs) that can be infused into donor...
The Department of the Army Medical Command awarded a $1,248,949 Project Grant to Massachusetts General Hospital through the Military Medical Research and Development program. The grant will fund research into stable mixed chimerism and tolerance of vascularized composite allografts via BCL-2 inhibition from September 30, 2022 to August 31, 2025. The Military Medical Research and Development program supports innovative biomedical research with the goals of improving military and public health...
The Department of the Army Medical Command awarded a $204,480 Project Grant to the Massachusetts General Hospital through the Military Medical Research and Development program. The grant will fund research into stable mixed chimerism and tolerance of vascularized composite allografts via BCL-2 inhibition from September 30, 2022 through August 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of improving...